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L. David Sibleyc
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Medicine, St. Louis, Missouri, USAc
Cryptosporidiosis is a serious diarrheal disease in immunocompromised patients andmalnourished children, and treatment is
complicated by a lack of adequate drugs. Recent studies suggest that the natural occurrence of a small gatekeeper residue in ser-
ine threonine calcium-dependent protein kinase 1 (CDPK1) of Cryptosporidium parvummight be exploited to target this en-
zyme and block parasite growth. Here were explored the potency with which a series of pyrazolopyrimidine analogs, which are
selective for small gatekeeper kinases, inhibit C. parvum CDPK1 and block C. parvum growth in tissue culture in vitro. Al-
though these compounds potently inhibited kinase activity in vitro, most had no effect on parasite growth. Moreover, among
those that were active against parasite growth, there was a very poor correlation with their 50% inhibitory concentrations
against the enzyme. Active compounds also had no effect on cell invasion, unlike the situation in Toxoplasma gondii, where
these compounds block CDPK1, prevent microneme secretion, and disrupt cell invasion. These findings suggest that CPDK1 is
not essential for C. parvum host cell invasion or growth and therefore that it is not the optimal target for therapeutic interven-
tion. Nonetheless, several inhibitors with lowmicromolar 50% effective concentrations were identified, and these may affect
other essential targets in C. parvum that are worthy of further exploration.
Cryptosporidiosis has recently gained increased recognition asa globally important cause of diarrheal disease in humans (1).
Human cryptosporidiosis is caused primarily by two species,
Cryptosporidiumparvum andC. hominis. AlthoughC. parvum also
infects agricultural animals and is acquired as a zoonosis,C. homi-
nis is transmitted from human to human. Infection occurs when
oocysts shed in the feces contaminate food or water and are acci-
dentally ingested. Oocysts are extremely environmentally resis-
tant and highly infectious, making the life cycle difficult to inter-
rupt (2). Following infection, most healthy individuals suffer only
temporary discomfort and go on to self-cure; however, cryptospo-
ridiosis is a serious, life-threatening infection in the immunocom-
promised (1). Recently, cryptosporidiosis has also been recog-
nized as a serious cause of morbidity in young children in Africa
and South Asia, being among the top three diarrhea-causing
agents (3). Complicating this situation, there are few effective
therapies for cryptosporidiosis, and the one FDA-approved drug,
nitazoxanide, is not effective in immunocompromised patients or
malnourished children (4).
Cryptosporidium is a deep-branching member of the phylum
Apicomplexa, and it differs in many ways from distantly related
parasites such as Toxoplasma gondii (5). Although Cryptospo-
ridium is intracellular during its replicative phase, it exists in a
membrane-bound compartment at the apical surface of intestinal
epithelial cells, remaining separated from the cytosol by a feeding
organelle (6). The genome of C. parvum is highly streamlined (7),
lacking many metabolic pathways while containing a large num-
ber of transporters involved in nutrient uptake (8). As a result of
its unique metabolism, and perhaps its unusual intracellular
niche, few drugs that are effective against related parasites act on
C. parvum or C. hominis (4). Therefore, there is a need to define
new targets and to identify compounds that effectively inhibit par-
asite growth. An added challenge in working with Cryptospo-
ridium is that it does not undergo continuous propagation in vitro,
although short-term tissue culture assays have been used to screen
for small-molecule inhibitors of C. parvum replication (9, 10).
Like other eukaryotes, Cryptosporidium contains a diverse
complement of protein kinases (11), including members of the
calcium-dependent protein kinase (CDPK) family that are ex-
panded in apicomplexans (12). The fact that CDPKs are plantlike
and absent from animal cells has made them attractive targets for
consideration in developing therapeutic interventions (13).Cryp-
tosporidium shares a unique property with T. gondii in having a
small Gly gatekeeper residue in CDPK1 (14, 15), a feature that is
unprecedented among kinases in animal cells (16). The impor-
tance of the gatekeeper residue has previously been used to engi-
neer kinases to acquire sensitivity to pyrazolopyrimidine (PP) an-
alogs, which are typically excluded by the bulky gatekeeper residue
in the ATP-binding pocket of normal kinases (17, 18). Because of
its naturally small gatekeeper, T. gondii CDPK1 (TgCDPK1) is
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highly sensitive to PP inhibitors (19, 20). Inhibition of TgCDPK1
blocks microneme secretion and prevents host cell invasion by T.
gondii (19, 21). The gene for CDPK1 is essential in T. gondii (19),
and a number of PP analogs have been developed to target this
enzyme in vitro (22, 23). In addition to the chemical genetic evi-
dence that large gatekeeper mutant forms of CDPK1 become re-
fractory to inhibition (19), the tight correlation between enzyme
in vitro 50% inhibitory concentrations (IC50s) and in vivo growth
inhibition 50% effective concentrations (EC50s) (24) argues that
CDPK is the primary target of PP inhibitors inT. gondii. Similarly,
several studies have explored the sensitivity of C. parvum CDPK1
(CpCDPK1) in vitro by using series of PP inhibitors, showing that
many were potent against the enzyme (25, 26). These findings
were further extended by showing that one such inhibitor, called
compound 1294, which was designed against TgCDPK1 (27), ef-
fectively blocks C. parvum growth in cell culture at submicromo-
lar concentrations and reduces oocyst shedding in an immuno-
compromised-mouse model (28). These studies suggest that
CpCDPK1might be a good target for which to explore additional
PP analogs.
Here we tested a broader array of PP-like compounds to estab-
lish the relative potencies with which they inhibit CpCDPK1 en-
zyme activity in vitro in comparison to their inhibition of parasite
growth in an in vitro cell culture assay. We were surprised to find
that although PP-like compounds are potent CpCDPK1 enzyme
inhibitors, there was a poor correlationwith their ability to inhibit
parasite growth. This suggests that CDPK1 is either not essential
or not the primary target of these compounds in vivo. Moreover,
unlike the situation inT. gondii, the active analogs used here block
only C. parvum growth and not parasite invasion. The findings
indicate that although somemembers of the PP scaffold are effec-
tive against C. parvum, they may act on targets other than
CpCDPK1, which may not be an appropriate target for the devel-
opment of inhibitors to combat cryptosporidiosis.
MATERIALS AND METHODS
Compounds. PP derivatives were synthesized as described previously (24,
29–31) and were95% pure, as determined by liquid chromatography-
mass spectrometry. Compound 22 is a trisubstituted pyrrole inhibitor of
PKG (32), and it was provided by Merck under a material transfer agree-
ment.
C. parvum strain propagation and purification of oocysts. The
AUCP-1 isolate ofC. parvumwasmaintained by repeated passage inmale
Holstein calves (IACUC-approved protocol). Oocysts were purified from
collected feces after sieve filtration, Sheather’s sugar flotation (33), and
discontinuous sucrose density gradient centrifugation (34). Oocysts were
washed and stored at 4°C in 50 mM Tris–10 mM EDTA, pH 7.2. Oocysts
were used within 1 to 2 weeks of initial isolation from stored feces, when
viability remained above 80% as judged by excystation.
Excystation of oocysts and purification of sporozoites. Sporozoites
were excysted by a modified form of a previously described procedure
(35). Briefly, purified oocysts (about 1  108) were washed in Hanks
balanced salt solution (HBSS) or phosphate-buffered saline (PBS) and
treated with an equal volume of 40% commercial laundry bleach for 10
min at 4°C. Oocysts were washed four times in PBS containing 1% (wt/
vol) bovine serum albumin (BSA). Oocysts were suspended in HBSS,
incubated for 60 min at 37°C, and then mixed with an equal volume of
warm 1.5% sodium taurocholate in HBSS. After excystation for 60min at
37°C, the sporozoite-oocyst-shell mixture was collected by centrifugation
and suspended inRPMI 1640medium containing 10% fetal bovine serum
and sporozoites were separated from oocyst shells and unexcysted oocysts
by filtration through 3-m Whatman Nuclepore filters. Purified sporo-
zoites were enumerated with a hemocytometer and used immediately for
infection of cell monolayers.
C. parvum growth or invasion assays with cell monolayers. HCT-8
cells were obtained from the ATCC (CCL244) and cultured in RPMI 1640
medium (Sigma) supplemented with 2 g of sodium bicarbonate per liter,
2.5 g of glucose per liter, a final concentration of 10% fetal bovine serum
(Bio-West), 1 antibiotic-antimycotic (Gibco), and 1 sodiumpyruvate
(Sigma). Cells were used to seed 48-well plates and grown to confluence
within 2 to 3 days. For growth experiments, sporozoites (5 104 to 1
105/0.1ml) inmediumwith serumwere added to each well and incubated
for 4 h at 37°C. Cells were rinsed three times with PBS, and then 0.3 ml of
a compound at various concentrations or a dimethyl sulfoxide (DMSO)
sham control was added to each well in triplicate. Incubation was contin-
ued for 48 h. For invasion experiments, sporozoites were premixed with
various compounds or a DMSO sham control for 15min and then 0.1-ml
volumes were added to wells in triplicate. After 4 h at 37°C, wells were
washed three times with PBS, followed by the addition of 0.3 ml of me-
dium with serum and 24 or 48 h of continued growth at 37°C. At the end
of each experiment, cells were chilled on ice and each sample consisting of
three wells was extracted with 100 l of cold TRIzol reagent (Invitrogen)
per well, combined, frozen quickly in dry ice, and stored at minus 80°C
until RNA harvest. For growth assays (see Fig. 5), sporozoites were added
to host cells and cell layers were washed after 4 h at 37°C and then incu-
bated for 24 h in medium without compounds. Following this establish-
ment of infection, compound 21 (6.25M) or compound 1 (10M)was
added at 24 h postinfection. At 24-h intervals, the medium was removed
and freshmedium containing fresh drug at the original concentrationwas
added to the remaining wells. As a positive control, one set of wells was
incubated with either compound 21 (6.25 M) or compound 1 (10 M)
immediately following the 4-h sporozoite invasion step and harvested at
24 h. At the end of each incubation step, cells were harvested with TRIzol
reagent and frozen as described above until purification of RNA. Experi-
ments were repeated two or more times with three technical replicates
included in each experiment.
C. parvum growth assays monitored by indirect fluorescent-anti-
body (IFA) assay. Following growth experiments performed as described
above, the medium was removed and cell layers were immediately fixed
and stained with antibody to C. parvum (SporoGlo; Waterborn, Inc.) as
previously described (36). Briefly, cells were fixed with methanol-acetic
acid (9:1) for 2 min, rehydrated, permeabilized by two successive washes
with a washing buffer containing 0.1% Triton X-100, blocked with 5%
normal goat serum, and stained with antibody overnight at 4°C. The
stained cells were washed twice with PBS, followed by water, and then
observed with an inverted fluorescence microscope with a 20 objective.
Infected cells containing replicating parasites appeared as fluorescent
clusters of infectivity or foci. The numbers of fluorescent particles within
each focus per 20 field were determined by automatic microscopic col-
lection of nine fields per well of a 96-well plate. These nine fields were
assembled into a singlemontaged image for eachwell, equating to approx-
imately 75% of the surface area of each well. The number of fluorescent
particles in each montage was determined with either Metamorph (Mo-
lecular Devices, Inc.) or Image J software and is expressed in fluorescent-
focus units (FFU). Experiments were repeated two or more times with
three technical replicates included in each experiment.
RNA isolation and RT-qPCR. Total RNA from TRIzol samples was
purified with Direct-zol RNA MiniPrep (Zymo Research) according to
the manufacturer’s directions, which included DNase1 digestion. Con-
centrations were determined and quality was assessed by measurement of
absorbance at 230, 260, and 280 nm. First-strand cDNA was synthesized
from total RNA with Superscript III (Invitrogen) according to the man-
ufacturer’s directions. Reverse transcription-quantitative PCR (RT-
qPCR) was performed with Power SYBR green PCRmaster mix (Applied
Biosystems Life Technologies) according to the manufacturer’s direc-
tions. Expression of human glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) employed primers 5=-CGACAGTCAGCCGCATCTT-3= (for-
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ward) and 5=-ATCCGTTGACTCCGACCTTC-3= (reverse). C. parvum
18S rRNAwas detected with primers 5=-TAGAGATTGGAGGTTGTTCC
T-3= (forward) and 5=-CTCCACCAACTAAGAACGGCC-3= (reverse).
Samples were heated to 50°C for 2 min, followed by 95°C for 10 min,
followed by 40 thermal cycles (95°C for 15 s and then 60°C for 1 min,
followed by a 60°C-to-95°C melt curve) of PCR amplification with an
Applied Biosystems 7500 real-time PCR detection system (Life Technol-
ogies). Triplicate reaction mixtures were prepared for each sample. Nor-
malized C. parvum 18S rRNA gene expression relative to that of the ref-
erence gene for GAPDH was calculated with ABI 7500 software version
2.3. Normalized gene expression was linear from a dose of 103 sporozoites
to a dose of 2.5105 sporozoites.
Protein purification. Plasmids expressing residues T71 to E538 of
CpCDPK1 (15) or full-length TgCDPK1 (24)were transformed intoEsch-
erichia coli BL21(DE3)-V2R-pACYC-LICLamP phosphatase-express-
ing cells, which were described previously (15). A single colony was inoc-
ulated into 5 ml of Terrific broth (TB) with ampicillin (100 g/ml) and
chloramphenicol (34 g/ml) and cultured overnight at 37°C. The next
day, the overnight culture was diluted into 250 ml of fresh TB with ampi-
cillin (100g/ml) and chloramphenicol (34g/ml). After growth for 3 to
3.5 h at 37°C, cultures were cooled to 15°C and induced with 0.3 mM
isopropyl--D-thiogalactopyranoside (IPTG) for CpCDPK1 or 1 mM
IPTG for TgCDPK1 during growth overnight. For CpCDPK1, the cell
pellet was then sonicated and purified with HIS-Select nickel affinity gel
(Sigma). For TgCDPK1, the cell pellet was lysed in CelLytic B 2 (Sigma)
with added lysozyme, Benzonase, and a protease inhibitor cocktail. The
proteins were purified with HIS-Select nickel affinity gel (Sigma) and
dialyzed in a buffer containing 50 mMTris-HCl (pH 7.5), 150 mMNaCl,
and 0.125%Chelex 100. Glycerol was added to 25%, dithiothreitol (DTT)
was added to a final concentration of 0.5 mM, and the proteins were
stored at80°C. Protein concentrations were determined by SDS-PAGE
separation and SYPRO-Ruby Protein Gel staining (Invitrogen) in com-
parison with a BSA standard.
CpCDPK1 enzyme assay. A coupled enzyme ATPase assay was used
to measure CpCDPK1 activity as described previously (15). The coupled
assay was carried out with 150 M reduced -NAD (NADH), 300 M
phosphoenolpyruvic acid, 50mMKCl, and a 3-U/mlmixture of pyruvate
kinase and lactate dehydrogenase (Sigma). The following conditions were
used for IC50 determination: 13 nM CpCDPK1, 50 M ATP, 50 M
Syntide-2 peptide (Calbiochem), and serial dilutions of inhibitors (10 pM
to 20 M) in a buffer containing 20 mMHEPES (pH 7.5), 30 mM NaCl,
10 mM MgCl2, 1 mM CaCl2, 2 g/ml BSA, 10 mM DTT, and 0.01%
(vol/vol) Tween 20. Compound dilutions were incubated with CpCDPK1
for 15 min at room temperature, and then ATP was added to initiate the
kinase reaction. After incubation for 40 min at 30°C, reactions were read
bymeasuring absorbance at 340 nmon aCytation3 plate reader (BioTek).
Assays were repeated two or more times, and average values were used to
determine IC50s by nonlinear curve fitting of normalized data with Prism
(GraphPad).
TgCDPK1 expression and enzyme assay. An enzyme-linked immu-
nosorbent assay (ELISA)-based method was used to measure TgCDPK1
activity as described previously (24). Syntide-2 peptide (Calbiochem) was
used to coat 96-well plates (Immulon 4HBX; Thermo Scientific) at 10
g/ml (100l/well) in carbonate coating buffer, pH 9.6, at 4°C overnight.
After being washed with 50 mM Tris-HCl (pH 7.5)–0.2% Tween 20, the
plates were blocked with 250 l of 3% BSA for 2 h at room temperature.
Kinase reactions were carried out at 30°C for 30 min in a kinase reaction
buffer consisting of 20 mMHEPES/KOH (pH 7.5), 10 mMMgCl2, 1 mM
DTT, 0.1 mM EGTA, 2.5 mM CaCl2, and 0.005% Tween 20. Purified
TgCDPK1 (15 nM) was added to serial dilutions of inhibitors (10 pM to
10 M) in kinase reaction buffer and incubated for 15 min at room tem-
perature. Reactions were initiated by the addition of ATP to a final con-
FIG 1 Structures of the compounds used in this study. Compound 21 is the original PP inhibitor, previously referred to as PP1 (49). Compound 22 is an
unrelated trisubstituted pyrrole that inhibits PKG (44). MW, molecular weight.
Kuhlenschmidt et al.
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centration of 50 M. After 30 min, the solution was removed and phos-
phorylated Syntide2 was detected with monoclonal antibody MS-6E6
(Cyclex Co.), followed by peroxidase-conjugated secondary goat anti-
mouse IgG. Reaction products were developed with the substrate
3,3=,5,5=-tetramethylbenzidine and detected by measuring absorbance at
450 nm. Assays were repeated two ormore times, and average values were
used to determine IC50s by nonlinear curve fitting of normalized datawith
Prism (GraphPad).
RESULTS
Choice of PP analogs.We selected a series of previously described
PP analogs designed to probe the expanded hydrophobic cavity of
CDPK1 that is created by the small gatekeeper residue. Included
were commonly used analogs such as 1-naphthyl-PP (1NA, com-
pound 1), 2-naphthyl-PP (2NA, compound 2), and 1-naphthyl-
methyl-PP (2NM, compound 3), as well as derivatives containing
isopropyl (compound 4) or cyclopentyl (compound 5) at the N1
position (Fig. 1) or modified at the C-3 position to contain a
benzothiaphene (compound 6). We also included several com-
pounds with bulkier phenyl-oxy-phenol or biphenyl groups at the
C-3 position (compounds 7, 8). Benzyl groupsmodified at theC-3
position (meta) have previously proven to be potent inhibitors of
TgCDPK1, so we included a series of these analogs here (com-
pounds 9 to 15), as well as similar compounds modified at C-4
(para) (compounds 16 to 17) or C-2 (ortho) (compound 18) and
several with dual substitutions on the benzyl ring (compounds 19
and 20). For comparison, we included the original PP1 com-
pound, 4-methyl-phenyl PP (compound 21) (Fig. 1). Compound
21 was originally described as an inhibitor of Src, which contains
Thr at the gatekeeper, although likemost of these compounds, it is
more potent inhibitor of kinases with small (i.e., Ala, Gly) residues
at the gatekeeper position (37). We also included a previously
described trisubstituted pyrrole inhibitor of PKG in apicomplex-
ans (compound 22 here, often referred to as compound 1 in the
Toxoplasma literature) (32).
PP analogs inhibit CpCDPK1 and TgCDPK1 with similar
potencies. We compared the potencies with which PP com-
pounds inhibit the activities of the CpCDPK1 and TgCDPK1 en-
zymes, whichwere recombinantly expressed in E. coli and purified
to homogeneity as described previously (15, 19). A previously de-
scribed ELISA was used to monitor the activity of TgCDPK1 (24),
as it provided consistent results between replicates. However, this
assay proved more variable when monitoring the activity of
CpCDPK1, and therefore, a more sensitive coupled enzymatic as-
say was used to monitor the activity of this enzyme, as described
previously (25). PP analogs potently inhibited both enzymes, with
IC50s ranging from low nanomolar to low micromolar (Table 1).
Because of different assay conditions were used, it is not possible
to directly compare the potencies with which a given compound
inhibits the two enzymes. Nevertheless, the relative rank of poten-
cies should remain the same if they have the same structure-activ-
ity relationship. Comparison of the IC50s for TgCDPK1 and those
for CpCDPK1 shows that there is a significant correlation between
the potencies of the compounds (Pearson correlation coefficient
[r], 0.6734; P  0.001) (Fig. 2A). The exceptions to this pattern
were themuchmore potent activities of compounds 1, 7, 9, and 21
against TgCDPK1 versus CpCDPK1; in contrast, compounds 12,
3, and 13 were more potent against CpCDPK1 (Fig. 2B). Com-
pound 22, an inhibitor of PKG, was a reasonably potent inhibitor
of both TgCDPK1 and CpCDPK1 in vitro, an effect consistent
with previous reports that this compound also targets small gate-
keeper kinases in vitro (38).
In comparing the relative potencies with which the various PP
analogs inhibit CpCDPK1 enzyme activity in vitro, several pat-
terns were evident (Table 1; Fig. 1). Among the naphthyl deriva-
tives modified at the C-3 position, compound 3 (1-naphthyl-
methylene)was themost potent, and its activity increasedwith the
replacement of the tertiary butyl group atN1with either isopropyl
(compound 4) or cyclopentyl (compound 5). Biaryl C-3 substitu-
ents such as compounds 7 and 8 lost potency, which likely reflects
the different angle imposed by both the direct aryl linkage and the
bulkier diphenyl groups. Compound 6 showed improved po-
tency, suggesting that the benzothiophene makes a favorable in-
teraction in the pocket. In terms of the smaller benzyl substituents,
modifications to themeta position (C-3) of the benzyl group were
all quite potent against CpCDPK1 (compounds 9 to 15). Modifi-
cation at the para position (C-4) with amethyl group (compound
16) lost potency relative to that of the C-3-substituted form (com-
pound 10), and this was further diminished by the substitution of
a bulkier methoxy group at C-4 (compound 17). In comparison,
substitution of a similar group at C-2 showed reasonable potency
against both CpCDPK1 and TgCDPK1 (compound 18). Double-
methyl substitutions at C-3 and C-4 (compound 19) improved
potency over that of the single para substitution (compound 16),
while Cl substitutions at C-2 andC-3 (compound 20)were similar
to the single C-3 substitution (compound 11) (Table 1; Fig. 1).
Overall, most of the PP inhibitors tested reasonably potently in-
hibited both CpCDPK1 and TgCDPK1.
Lack of correlation between enzyme inhibition and parasite
growth inhibition. We were interested in comparing the in vitro









1NA 1 0.00213 3.31050 2.56
2NA 2 0.00213 0.02970 15.90
1NM 3 0.16950 0.00730 NIc
CZ33 4 0.00089 0.00290 14.11
CZ34 5 0.00015 0.00010 8.06
CZ43 6 0.00004 0.00060 NI
CZ29 7 0.00397 0.22560 8.02
CZ30 8 2.08600 10.00000 6.18
Bn 9 0.00036 0.00810 19.34
3MB 10 0.00399 0.01000 NI
3ClB 11 0.00069 0.00350 NI
3IB 12 0.01295 0.00020 NI
3BrB 13 0.00964 0.00670 NI
CZ42 14 0.00026 0.00480 NI
CZ31 15 0.00044 0.00350 8.96
CZ15 16 0.06840 0.17530 4.08
CZ20 17 8.15800 5.89800 7.68
CZ19 18 0.01471 0.03870 NI
CZ23 19 0.00787 0.00950 NI
CZ72 20 0.00238 0.00410 NI
PP1 21 0.00192 0.06020 2.03
Compound 1 22 0.04041 0.33360 13.47
a IC50s are enzyme assay results.
b EC50s reflect growth as determined by PCR assay.
c NI, no inhibition at 25 M.
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inhibition of CpCDPK1 enzyme activity to inhibition of parasite
growth in cell culture. The expectation is that if inhibition of
CpCDPK1 is important for growth, there should be a correlation
between activity against the enzyme and the ability to block para-
site growth. For these comparisons, we monitored the growth of
C. parvum in monolayers of HCT-8 cells by either a PCR-based
method or an immunofluorescence-based assay as described pre-
viously (36). Under these conditions, C. parvum expands for sev-
eral days before becoming growth arrested. Inhibition is expressed
as the growth level relative to that of an untreated control. We
utilized freshly isolated and purified sporozoites for infection in
order to maximize the chance to measure inhibition of invasion,
although inhibitors were left in for the duration of the assay used
for EC50 determination.
Unlike the enzyme activity assay, where nearly all of the com-
pounds were potent inhibitors, many of them failed to inhibit
parasite growth at the highest concentration tested (25 M) (Ta-
ble 1). Approximately half of the compounds showed inhibition in
this range, allowing us to determine EC50s that ranged from2 to
20 M (Table 1). Although some loss of potency might be ex-
pectedwhen treatingwhole-cell cultures, these valueswere 100- to
1,000-fold higher than those necessary for effective inhibition of
the enzyme (Table 1). Moreover, when we compared the relative
enzyme inhibitory potencies of the compounds in vitro with their
abilities to block parasite growth, there was a significant and neg-
ative correlation between the EC50s and IC50s (r 	 0.58; P 
0.005) (Fig. 2B). When the paired IC50s-EC50s of each compound
were plotted together, it was apparent that (i) many PP analogs
lack activity against the parasite, (ii) those that are active are only
modestly so, and (iii) there is little correlation between the inhi-
bition of enzyme activity and parasite growth (Fig. 2D).
PP analogs act on growth, not invasion, ofC. parvum. Previ-
ous studies have shown that PP analogs inhibit TgCDPK1, block
microneme secretion, and therefore prevent cell invasion (19). To
determine if the active PP analogs studied here have a similar
mechanism, we compared the effects of potent inhibitors of inva-
sion with C. parvum growth by using specific assays to separate
these phases of infection. For invasion, we treated sporozoites
briefly (15min) with compounds, added them to cell monolayers,
and incubated them for 4 h beforewashing out the compound and
culturing the cells in fresh medium. For growth, the compounds
were added 4 h after infection with purified sporozoites and then
left in for the duration of the experiment. Under these conditions,
compounds 1 and 21 effectively inhibited growth only when
added at 4 h postinfection and left in the culture continuously
(Fig. 3). The same result, that the compounds were specific for
inhibition of growth,was obtainedwith a PCR-based assay (Fig. 3)
and an IFA assay that measured parasite foci by semiautomated
microscopy (Fig. 4). To extend these findings further, we used
concentrations that were approximately three times the EC90s of
compounds 1 and 21 and added the compounds at 24 h after
infection. Evenwhen added at this late time point, the compounds
effectively prevented growth over an extended culture period.
These same doses of compounds provided sterilizing protection
when added at 4 h postinfection (Fig. 5). In composite, these find-
ing clearly show that effective PP analogs, at least compounds 1
and 21, work only by blocking growth and have no effect on C.
parvum sporozoite invasion.
DISCUSSION
We have used a series of well-studied PP analogs that target small
gatekeeper kinases to explore the relationship between inhibition
of CDPK1 activity in vitro and blocking of C. parvum growth in
cell culture. As expected, PP analogs were potent inhibitors of the
CpCDPK1 enzyme and their activities were largely similar to that
against TgCDPK1, although there were notable differences in
FIG 2 Comparison of the activities of TgCDPK1 and CpCDPK1 enzyme inhibitors and inhibition of C. parvum growth. (A) Comparison of the sensitivities of
the CpCDPK1 and TgCDPK1 enzymes to inhibitors in vitro. Linear regression is shown; dashed lines indicate 95% confidence intervals. (B) Plot of IC50s of
individual compounds for the CpCDPK1 and TgCDPK1 enzymes. Linear regression is shown; dashed lines indicate 95% confidence intervals. (C) Sensitivity
of CpCDPK1 enzyme activity (IC50) versus growth (EC50) ofC. parvum in culture to inhibitors. (D) Plot of IC50s of individual compounds for CpCPKD1 enzyme
activity versus EC50s against C. parvum growth. IC50s and EC50s are from Table 1.
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some compounds. In contrast to previous studies with T. gondii,
there was little correlation between the activities of PP inhibitors
against the CpCDPK1 enzyme in vitro and their abilities to inhibit
C. parvum growth in cell culture. Moreover, the activity of PP
analogs that did inhibit growth was not dependent on blocking of
cell invasion, unlike the situation for T. gondii. These findings
suggest that although C. parvum has a conserved small gatekeeper
residue in CPKD1, this enzyme may not be a good target for the
development of inhibitors to prevent growth in vivo.
The majority of the PP inhibitors tested were similarly potent
against TgCDPK1 and CpCDPK1 enzymes in vitro; however, dif-
ferences in the potencies of some analogs were seen. These differ-
ences likely result from differences in the structure of the ATP-
binding pocket, despite the closely similar crystal structures of
these two proteins (14, 15, 20). Previous cocrystal structures with
selected PP analogs (14, 20) could be extended to further refine
these differences and design compounds with improved potency;
however, in the case of CpCDPK1, this effort may not be war-
ranted, given the discordant in vivo sensitivity of C. parvum
growth to these inhibitor, as discussed below.
Consistent with previous reports (25, 26), we observed that a
number of PP analogs were potent inhibitors of CpCDPK1 activ-
ity in vitro. Among the naphthyl derivatives modified at the C-3
position, linkage through a methylene group, as in compound 3
(1-naphthyl-methylene), was more potent that the direct linkage
in compounds 1 and 2. Modification of the N1 position from
tertiary butyl (compound 3) to isopropyl (compound 4) or cyclo-
pentyl (compound 5) further improved the potency of compound
3 against the CpCDPK1 enzyme. However, even among this small
set, it was already evident that there was a lack of correlation be-
tween inhibition of enzyme activity and inhibition of parasite
growth, as the twomost potent 1-naphthyl-methylene derivatives
(compounds 5 and 6) had no activity against the parasite. Indeed,
four of the six most potent inhibitors of enzyme activity (com-
pounds 3, 4, 5, 6, 12, and 13) had no activity against C. parvum
growth, and this pattern continued when the entire series was
compared. One possible explanation for these findings is that the
PP analogs tested here were not able to gain access to the target in
vivo. However, this seems unlikely, given that they all conform to
Lipinski’s rule of five, which characterizes bioactive drugs on the
basis of their small size (molecular mass of 
500 Da) and low
hydrophobicity (calculated log octanol/water partition coefficient
[CLogP],
5) (39), as listed in Fig. 1. Moreover, previous studies
have shown that these compounds easily enter mammalian cells
(18, 30) and are active against the related parasite T. gondii even
when it is intracellular (24). Instead, the lack of correlation be-
tween IC50s and EC50s suggests that CDPK1 is likely not an essen-
tial enzyme inC. parvum and that CDPK1 is not the target of those
PP analogs that are effective against parasite growth. Recent ad-
vances in the development of molecular genetics for C. parvum
(40) might be used to test this hypothesis; however, the current
system used to generate transgenic parasites still requires propa-
gation in mice and thus is not amenable to essentiality testing in
vitro.
Our findings differ from observations with T. gondii showing
that PP analogs block the function of CDPK1 in controlling mi-
FIG 3 Comparison of the effects of compounds on invasion and growth of C. parvum in HCT-8 cells in vitro. Compounds were tested in C. parvum growth or
invasion assays by using RT-qPCR assays to quantify parasite numbers as described inMaterials andMethods. Invasionwasmonitored by pretreatment (15min)
of isolated sporozoites, followed by challenge of monolayers and removal of the compound (Cmpd) at 4 h. Growth was monitored by inoculation of isolated
sporozoites, followed by the addition of compounds at 4 h postinfection and continual culture in the compounds. Relative expression values represent the values
of experimental samples (plus drug) normalized to those of control samples (no drug) (ratio of gene expression at each drug concentration/control). Triplicate
PCR assays were performed, and relative expression values are presented as means  standard deviations (n 	 3). Curve fitting was performed by nonlinear
regression with Prism (GraphPad). EC50s are provided in Table 1.
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croneme secretion and hence prevent host cell invasion (24). In
contrast, those PP analogs that were potent in the C. parvum
growth inhibition assay had no activity when added only during
invasion. In T. gondii, microneme secretion is controlled by cal-
cium fluxes that are thought to activate CDPK1 (41) and facilitate
other steps in microneme exocytosis (42). Recent evidence also
implicates CDPK3 and PKG inmicroneme secretion control in T.
gondii (43). This pathway is likely conserved in the coccidian par-
FIG 4 Effects of selected compounds on C. parvum growth as determined by IFA assays. (A) Dose response of inhibition of growth was monitored by IFA assay
detection of intracellular C. parvum forms as described inMaterials andMethods. FFU values represent means standard deviations (n	 3). Curve fitting was
performed by nonlinear regression with Prism (GraphPad). (B) Representative images of IFA staining of control and compound (Cmpd) 1- and 21-treated
cultures. The upper set of images depicts representative single-well montage photomicrographs (comprising nine fields) of a 96-well plate as described in
Materials andMethods. The lower images are each enlargements representing one of the nine image frames shown in the corresponding upper images. EC50s are
provided in Table 1. Scale bars, 200 m.
FIG 5 Time dependence of the sensitivity of C. parvum growth to compounds. (A) Sensitivity of C. parvum growth to compound (Cmpd) 1. (B) Sensitivity of
C. parvum growth to compound 21. Open circles, growth in the absence of inhibitors; black triangles, inhibitors added at 4 h postinfection (dashed arrow)
representing a positive control demonstrating that compounds completely blocked C. parvum growth during the first 24 h; filled circles, inhibitors added at 24
h postinfection (solid arrow) and then replaced every 24 h thereafter (see Materials and Methods for additional details). Relative expression is defined as
normalized expression (see Materials and Methods) at the time points indicated with and without the drug divided by the normalized expression at the
initial 4-h time point (representing initial sporozoite invasion but no growth) as described in Materials and Methods. Values represent means standard
deviations (n 	 3).
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asite Eimeria tenella, where treatment with compound 22, an in-
hibitor of PKG, blocked microneme secretion and host cell inva-
sion (44). Hence, it was surprising to find that neither PP
inhibitors that were active against CpCDPK1 in vitro nor com-
pound 22, a PKG inhibitor that also acts on CDPK1 in vitro, were
able to block C. parvum invasion. Cryptosporidium also contains
apical organelles called micronemes, which are enriched in adhe-
sive domains involved in cell attachment (45). Although less well
studied than in T. gondii, elevated calcium also appears to be im-
portant in the release of microneme proteins in sporozoites of C.
parvum (46). The failure of PP inhibitors to block cell invasion by
C. parvum suggests that the process of microneme secretion dif-
fers from that described in T. gondii. It is possible that sporozoites
have already upregulated micronemal protein on their surface
during excystation, such that inhibition does not block invasion.
CpCPDK1 has been shown to be consistently expressed relatively
late in infection, peaking after 24 h and continuing beyond 48 h
(47), suggesting that it may be involved in a later stage of intracel-
lular growth.Hence, CDPK1might become important in control-
lingmicroneme secretion during the transition from type I to type
II meronts, between which merozoites exit from one cell and in-
vade new cells. However, we failed to observe a consistent rela-
tionship between PP inhibitors that block growth and the potency
with which they inhibit CpCDPK1 enzyme activity. These results
suggest that CpCDPK1 may not be involved in the release of mi-
cronemes or in cell invasion by C. parvum. In this regard, it is
instructive that the ortholog of CDPK1 in P. berghei (called
CDPK4 for historic reasons) is not required for microneme secre-
tion but rather functions in male gametocyte exflagellation (41).
Given the deep-branching position of Cryptosporidium (5), it is
not surprising that CDPK1 orthologues have diverged in function
since the common origin of the Apicomplexa.
Our findings differ from a previous report demonstrating
that a modified PP analog called 1294 was potent in blocking C.
parvum invasion when the drug was added for only 2 h during
the initial infection. Compound 1294 contains a 6-ethoxy-
naphthyl in direct aryl linkage with C-3 of the PP scaffold and
amethyl-piperidine at the N1 position (27). Compound 1294 is
a potent inhibitor of C. parvum CDPK1 enzyme activity in vitro
(27). However, the above evidence that the potency with which
PP analogs inhibit CpCDPK1 enzyme activity does not corre-
late with growth inhibition suggests that the potency of 1294
may be due to its action on an unrelated yet essential target.
Others have shown that mitogen-activated protein kinase 1
(MAPK1) is a secondary target of some PP analogs in T. gondii,
notably, 1NM (compound 3) (21, 48). TgMAPK contains a Ser
gatekeeper residue, and mutations in the nucleotide-binding
pocket render it resistant to PP analogs, including 1NM (com-
pound 3). Therefore, itmay be instructive to explore other kinases
to define the target(s) of PP analogs that are active against C.
parvum. Cryptosporidium contains more than 70 protein kinases,
including seven CDPKs, although of these, only CDPK1 contains
a glycine gatekeeper (13, 25). It is possible that additional protein
kinases with smallish residues such as A/T/S are alternative targets
for the PP inhibitors examined here. In this regard, the com-
pounds that blocked C. parvum growth the most potently were 1,
16, and 21. Although genetic approaches have been very powerful
in validating the target of PP analogs in T. gondii (19), it has not
been possible to use such techniques with C. parvum previously.
With the advent of stable transformation (40), such tools that can
be used to both validate and discover the true targets of inhibitors
in C. parvum may be available soon.
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